Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Double-blind, Dose-ranging Study to Evaluate GSK573719 in Combination With Fluticasone Furoate, Fluticasone Furoate Alone, and an Active Control of Fluticasone Furoate/Vilanterol Combination in Subjects With Asthma
Brief Summary: Brief Summary: The purpose of this study is to characterize the dose response of GSK573719 in combination with Fluticasone furoate 100mcg in patients with asthma. Treatment with inhaled Fluticasone furoate and Fluticasone furoate/Vilanterol are included as an active control.

Detailed Description: Long acting muscarinic receptor antagonists (anti-cholinergic bronhcodilator) exert their effects via distinct and complementary bronchodilator mechanisms on large and small airways. Most of the experience with older anti-cholinergics had been with acute use and little is known about their effect in chronic use in asthma. This is a multicenter, randomized, double-blind, crossover study to evaluate 5 doses of inhaled GSK573719 inhaled over 14 days in patients with asthma. Fluticasone furoate (100 mcg) and Fluticasone furoate/Vilanterol (100/59mcg) will be included as an active comparator. Each eligible subject will receive a sequence of 3 of 7 potential treatments for a total of 3 treatment periods per subject. The total duration of subject participation is approximately 14 weeks.


Options:
A: Arm Label: Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg | Arm Label: Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg | Arm Label: Arm 3: Fluticasone Furoate 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate/ Vilanterol 200/25 mcg; Assigned to Arm(s): Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate/ Vilanterol 100/25 mcg; Assigned to Arm(s): Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100 mcg; Assigned to Arm(s): Arm 3: Fluticasone Furoate 100 mcg
B: Arm Label: FF/VI 200/25mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: GW685698/GW642444 | Arm Label: Fluticasone propionate 500mcg twice daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: CCI18781 | Intervention Type: DRUG; Name: GW685698/GW642444; Assigned to Arm(s): FF/VI 200/25mcg once daily | Intervention Type: DRUG; Name: CCI18781; Assigned to Arm(s): Fluticasone propionate 500mcg twice daily
C: Arm Label: Fluticasone Furoate (FF); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF | Arm Label: Fluticasone Furoate /Vilanterol (VI); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/VI | Arm Label: Fluticasone Furoate/GSK573719; Type: EXPERIMENTAL; Interventions: Drug: FF/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF; Assigned to Arm(s): Fluticasone Furoate (FF) | Intervention Type: DRUG; Name: FF/VI; Assigned to Arm(s): Fluticasone Furoate /Vilanterol (VI)
D: Arm Label: GSK573719 15.6 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 31.25 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 125 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 250 mcg; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 15.6 mcg twice-daily; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: GSK573719 31.25 mcg twice daily; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GSK573719 Active treatment or Placebo, Procedure: GSK573719 (Sub-group cohort), Drug: Salbutamol/Albuterol | Intervention Type: DRUG; Name: GSK573719 Active treatment or Placebo; Assigned to Arm(s): GSK573719 125 mcg, GSK573719 15.6 mcg, GSK573719 15.6 mcg twice-daily, GSK573719 250 mcg, GSK573719 31.25 mcg, GSK573719 31.25 mcg twice daily, GSK573719 62.5 mcg, Matched Placebo | Intervention Type: PROCEDURE; Name: GSK573719 (Sub-group cohort); Assigned to Arm(s): GSK573719 125 mcg, GSK573719 15.6 mcg, GSK573719 15.6 mcg twice-daily, GSK573719 250 mcg, GSK573719 31.25 mcg, GSK573719 31.25 mcg twice daily, GSK573719 62.5 mcg, Matched Placebo | Intervention Type: DRUG; Name: Salbutamol/Albuterol; Assigned to Arm(s): GSK573719 125 mcg, GSK573719 15.6 mcg, GSK573719 15.6 mcg twice-daily, GSK573719 250 mcg, GSK573719 31.25 mcg, GSK573719 31.25 mcg twice daily, GSK573719 62.5 mcg, Matched Placebo

Answer: C